PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Afatinib Significantly Improves PFS in Japanese NSCLC Patients: BI Japan
July 31, 2012
- Kyowa Kirin Launches Apokyn for Parkinson’s Disease
July 31, 2012
- Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
- Takeda Resubmits NDAs to US FDA for Alogliptin
July 31, 2012
- DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
- Kyowa Kirin’s 1st Half Pharmaceuticals Business Log 9.2% Sales Rise, but Operating Profits Fall
July 30, 2012
- US FDA Withholds Approval for Injectafer Due to Manufacturing Facility Issues: Daiichi Sankyo
July 30, 2012
- Approval for Once-Monthly Aripiprazole Hits Snag in US: Otsuka
July 30, 2012
- DSP, Nitto Denko Initiate PII Studies for Transdermal Patch Lonasen
July 30, 2012
- Eisai Receives Approval in Europe for Antiepileptic Perampanel; Launch in September
July 30, 2012
- Market Exclusivity for Lunesta Extended 6 Months in the US: DSP
July 30, 2012
- Celgene Initiates PII Trial in Japan for Revlimid in Treatment-Naïve Patients with Multiple Myeloma
July 30, 2012
- Pfizer Japan Files NDA for Prevnar 13 for Infant Use
July 30, 2012
- Kobayashi Kako Completes Construction of Anticancer Drug Manufacturing Facility
July 30, 2012
- Alfresa Launches Advanced Temperature-controlled Distribution Service
July 30, 2012
- Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps
July 30, 2012
- Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
- Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
- Serum Ca Levels Show No Increase in Coadministration of Forteo, Activated Vitamin D3: Eli Lilly Japan
July 27, 2012
- Keizai Doyukai Chairman Hasegawa Instructs Takeda to Create Countermeasures for Risk of Violence in Emerging Countries
July 27, 2012
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…